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In this study, we compare patients' risk-taking and spending behaviors to their willingness to pay (WTP)
for novel implants in a joint arthroplasty. 210 patients were surveyed regarding risk-taking and spending
behavior, and WTP for novel implants with either increased-longevity, increased-longevity with higher
risk of complications, or decreased risk of complications compared to a standard implant. Patients with
increased recreational risk-taking behavior were more WTP for increased-longevity. Patients who
“rarely“ take health-risks were more WTP for decreased risk of complications. Patients with higher
combined risk scores were more WTP for all novel implants. Patients who paid more than $50,000 for
their current car were more WTP for decreased complications. This study shows that patients' risk taking
and spending behavior inﬂuences their WTP for novel implants.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
As healthcare policy makers in the United States continue to
seek to limit the growing costs of healthcare there is an increasing
interest in utilizing healthcare models that emphasize better cost-
awareness by all parties involved. Consequently, this focus brings
forth new challenges for both the surgeon and the patient, as both
would like to utilize the highest quality materials, implants, de-
vices, etc. [1], but also we must learn to increasingly see cost as a
signiﬁcant factor in healthcare decisions. As such, healthcare
models that increasingly “share the cost”with the patient can be an
effective means of increasing the patient’s role in healthcare de-
cisions where cost is a signiﬁcant factor.
Various studies in the past have used “willingness-to-pay” (WTP)
as ameans ofmeasuring howmuch value a patient places on a certain
procedure or device [1e5]. While WTP is most speciﬁcally applicable
to a system where the patient shares a higher burden of healthcare
costs,WTP data is also indicative of what type of care or interventionsclosed potential or pertinent
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d/4.0/).are actually important to the patient and can help guide healthcare
administration in even traditional insurance models where patients
pay little more than the premiums [3]. However, WTP data is perhaps
most valuable to determine whether patients are willing to share the
cost for an “upgraded” procedure. As an earlier study by Schwarzkopf
et al. showed, only 20% of patients at their institution were satisﬁed
with a “standard of care” implant for total knee arthroplasty (TKA) or
total hip arthroplasty (THA), while 86% of patients werewilling to pay
for an upgraded prosthesis [4]. Therefore, WTP data may play an
especially important role as further restrictions are placedon surgeons
and patients regarding which total joint replacement (TJR) prostheses
will be covered by payers, further placing patients’ unease over
settling for “standard-of-care” quality at oddswith the goals of cutting
healthcare costs.
TJRs, especially TKAs and THAs, are widely regarded as an
effective treatment for end-stage joint arthritis [6, 7]. Each year,
over 800,000 TKA and THA operations are performed [8, 9] and as
the population in the United States ages, this number is projected to
increase dramatically in the coming years [10, 11]. Various studies
have found TJRs to be among the more cost-effective procedures
when considering quality-of-life years gained per amount spent
[12e17]. However, the cost of TJR operations, especially THA and
TKA operations has increased substantially over the past decade,
while reimbursement for the procedures has not increased simi-
larly [9] e in fact, from 1999 to 2007, Medicare reimbursement
declined by 20% for TKA and 21% for THA [18]. Consequently, this
has left many surgeons and patients feeling frustrated over then of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
Table 1
Descriptions of novel implants.
‘Standard’ implant: 15 year lifespan with 3% reoperation risk
Novel implant 1: 25 year lifespan with 3% reoperation risk
Novel implant 2: 25 year lifespan with 5% reoperation risk
Novel implant 3: 15 year lifespan with 1% reoperation risk
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rather than quality [1]. To add to this dilemma, advances in implant
technology for THA and TKA operations have led to the creation of
various novel implants that may have superior longevity and
decreased risks of complications, though at an increased cost which
is unlikely to be covered by many insurances.
Therefore, considering the direction of healthcare policy-
making, it is important to elucidate the factors that are associated
with patients’ WTP for novel TJR prostheses. The purpose of this
study is to identify which patient characteristics are most associ-
atedwith aWTP for novel, improved implants.We hypothesize that
certain risk taking behaviors and spending habits will be associated
with an increased WTP for a novel implant. Although some studies
have previously sought to correlate patient demographics or in-
come with WTP for TJR implants, including a previous work by
Schwarzkopf et al. [19], no previous study has observed how pa-
tients’ behavioral patterns or lifestyle choices contribute to their
willingness to be treatedwith a novel technology and theirWTP for
novel TJR implants. Consequently, our work adds to the growing
body of literature concerning risk aversement from novel tech-
nology and WTP for total joint arthroplasty prostheses.
Material and Methods
Design and sample
The study was approved by our institutional review board. We
conducted a prospective cross-sectional survey among patients
attending tertiary medical center. All the patients included in the
studywere enrolled during their visit at the Orthopaedic and Arthritis
center while waiting for their rheumatology clinic visit. Inclusion
criteria included: presenting to the rheumatology clinic, willing and
able to complete and comprehend the survey in English, being be-
tween the ages of 18e89 years old. Exclusion criteria included if the
patient was currently scheduled for joint replacement surgery or if he
had joint replacement surgery in the past. All patients that met in-
clusion criteria were invited to participate by a research assistant
during the clinic visit in the before or after their rheumatology
appointment. All completed surveys were collected and stored by the
research staff. During the course of the clinic visit and the survey no
educational material discussing implant characteristics, price or
arthroplasty procedure cost was provided to the patients.
Survey instrument
Subject demographics were collected in the survey as well as
patients’ risk taking behavior in different aspects of their life and
daily activity (Appendix I).
Patient willingness to pay and their life style risk taking
behavior were examined with relation to different novel implant
attributes. We presented to the patient features of a ‘standard’
implant which included longevity of about 15 years and risk of
short-term complications (e.g. infection, fracture, dislocation, or
nerve injury) estimated at 3% during the ﬁrst postoperative year.
We asked whether patients would be willing to pay, as well as the
amount, to the cost of three ‘novel implants’ (The amount the pa-
tients were willing to add as a co-payment was entered as free text
into the survey). We than asked the patient to deﬁne his risk taking
behavior in different aspects of his daily life and recreational
activity.
The 3 novel implants that were presented in the survey had the
following presumed characteristics: 1) proposed longevity of 25
years accompanied by the same 3% risk of short-term complica-
tions; 2) proposed longevity of 25 years associated with an
increased (5%) risk of complications; and 3) proposed standardlongevity (15 years) associated with a lower 1% risk of complica-
tions (Table 1).
Statistical analysis
To compare the willingness to pay (WTP) of groups of patients
with different risk taking behavior and different spending habits,
we categorized patients based on their answer to each individual
question concerning risk taking behavior or spending habits. Using
these groupings, we then compared theWTP for the three different
implant choices across the groups. A Pearson Chi Square test was
used to ﬁnd statistical differences in WTP between these groups.
To better analyze overall trends in risk-taking behavior and
WTP, the average risk score was calculated for each patient. This
was achieved by assigning numbers to each of the patient re-
sponses in regard to frequency of risk-taking behavior; the number
0 corresponded to the response “never,” 1 to the response “rarely,”
2 to the response “sometimes,” 3 to the response “often,” and 4 to
the response “very often.” However, this number scale was
reversed for health risk-taking behavior, with the number 0 corre-
sponding to the response “very often” and the number 4 corre-
sponding to the response “never.” The scores for each of the
risk-taking categories were summed and the patients were then
divided into groups of “low,” “medium,” and “high” combined risk-
taking scores using cutoffs of less than 5 for “low,” 5 to 9 for “me-
dium,” and 10 or more for “high.” These groups were then
compared using the Pearson Chi Square test.
Results
Two hundred and ﬁfty-one patients at the Orthopedic and
Arthritis Center were screened for study eligibility and approached
in clinic. Of those, 210 (84%) agreed to participate and 195 (78%)
completed the questionnaire. Out of the 195 study participants
recruited from the ofﬁces of 4 clinicians in the 9 months, 32% were
male; average age was 56 years (22e89 years); 51% were <60 years
old, 35% between 60e70 years old, and 14%  70 years old.
Comparing patients grouped based on their response to how
often they participate in recreational risk-taking, there was a sig-
niﬁcant difference (p¼ 0.033) between groups in their WTP for a
novel implant with a proposed 25eyear longevity and a 3% reop-
eration risk (novel implant 1) (Table 2). Amongst these groups,
those patients who “very often” participated in recreational risk-
taking were the most likely to be willing to pay for novel implant
1 (increased longevity), while those patients who reported “never”
participating in recreational risk-taking were the least likely to be
willing to pay for novel implant 1 (increased longevity). There was
no signiﬁcant difference amongst these groups in terms of WTP for
novel implants with either a 25 year longevity with a 5% reopera-
tion rate (novel implant 2) or a 15 year longevity with a 1% reop-
eration rate (novel implant 3).
Comparing patients grouped based on their response to how
often they take health risks (i.e. smoking), there was a signiﬁcant
difference between groups in their WTP for novel implant 3
(decreased risk) (p¼ 0.032). Those patients who reported taking
health risks “very often” were the least likely to pay for novel
implant 3, while those patients who reported taking health risks
“rarely” were the most likely to pay for novel implant 3 (decreased
Table 2
Risk-taking behavior and willingness to pay for implant upgrades.
Willingness to pay for:
25 year lifespan with 3%
reoperation risk
25 year lifespan
with 5% reoperation risk
15 year lifespan with 1%
reoperation risk
Recreational risks Never 33.0% 19.8% 24.4%
Rarely 54.9% 39.2% 33.3%
Sometimes 56.8% 25.0% 40.5%
Often 50.0% 20.0% 10.0%
Very often 66.7% 33.3% 33.3%
Chi square (p-value): 10.464 (0.033)* 6.644 (0.156) 5.470 (0.242)
Health risks Never 36.8% 33.3% 37.8%
Rarely 54.7% 32.8% 39.1%
Sometimes 43.5% 19.7% 23.0%
Often 38.1% 14.3% 14.3%
Very often 42.9% 28.6% 0.0%
Chi square (p-value): 3.907 (0.419) 5.262 (0.261) 10.581 (0.032)*
Career risks Never 42.9% 23.9% 28.6%
Rarely 57.1% 28.6% 31.0%
Sometimes 42.9% 30.0% 36.8%
Often 33.3% 50.0% 33.3%
Very often 33.3% 33.3% 0.0%
Chi square (p-value): 3.227 (0.521) 2.381 (0.666) 1.876 (0.759)
Financial risks Never 41.9% 21.9% 23.3%
Rarely 42.9% 27.5% 30.0%
Sometimes 56.8% 27.8% 41.7%
Often 50.0% 40.0% 30.0%
Very often 0.0% 100.0% 0.0%
Chi square (p-value): 3.393 (0.494) 4.569 (0.334) 4.347 (0.361)
Safety risks Never 35.6% 21.3% 24.7%
Rarely 56.9% 28.1% 41.4%
Sometimes 51.7% 28.6% 25.0%
Often 44.4% 44.4% 22.2%
Very often 50.0% 50.0% 16.7%
Chi square (p-value): 7.135 (0.129) 4.540 (0.338) 5.894 (0.207)
Social risks Never 35.5% 18.7% 20.3%
Rarely 43.8% 23.9% 31.3%
Sometimes 60.4% 37.7% 37.7%
Often 50.0% 41.7% 41.7%
Very often 50.0% 0.0% 0.0%
Chi square (p-value): 7.951 (0.093) 8.075 (0.089) 6.559 (0.161)
Combined risk Low 23.3% 11.6% 11.6%
Medium 50.9% 28.4% 34.5%
High 54.1% 37.8% 35.1%
Chi square (p-value): 10.990 (0.004)* 7.544 (0.023)* 8.520 (0.014)*
* p < 0.01.
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their WTP for novel implants 1 or 2 (Table 2).
Comparing patients grouped based on their reported frequency
of taking career risks, ﬁnancial risks, safety risks, or social risks;
there was no signiﬁcant difference in WTP for novel implants 1, 2,
or 3 amongst these groups (Table 2).
There was a signiﬁcant difference in WTP for novel implants 1, 2,
and 3 amongst patients grouped by their combined risk score
(p¼ 0.004, p¼ 0.023, p¼ 0.014; respectively) (Table 2). Those pa-
tients with a “high” combined risk score were the most likely to be
willing to pay for either novel implant 1, 2, or 3. Patients with a “low”
combined risk score were the least likely to be willing to pay for
either novel implant 1, 2, or 3. There were 44 patients with a “low”
combined risk score, 113 patients with a “medium” combined risk
score, and 38 patients with a “high” combined risk score (Table 2).
Comparing patients grouped by their response to how much
they paid for their current car, there was a signiﬁcant difference in
WTP for novel implant 3 (decreased risk) between groups
(p¼ 0.038). Those patients who paid more than $50,000 for their
current car were the most likely to be willing to pay for novel
implant 3 (decreased risk), while those patients who paid less than
$10,000 for their current car were the least likely to be willing to
pay for novel implant 3 (decreased risk) (Table 3). There was nosigniﬁcant difference in WTP for novel implants 1 or 2 when pa-
tients were grouped by how much they paid for their current car.
Comparing patients grouped by their response to howmuch they
paid for their current TV, therewas a signiﬁcant difference inWTP for
both novel implant 1 and novel implant 3 (p¼ 0.005 and p¼ 0.006,
respectively). Those patients who do not own a TV were the most
likely to be willing to pay for novel implant 1 (increased longevity
without increased risk),while thosepatientswhopaid less than$500
for their current TV were the least likely to pay for novel implant 1.
Those patients who paid $1,000 to $2,000 (or more than $2,000) for
their TV were the most likely to bewilling to pay for novel implant 3
(decreased risk), while patients who paid less than $500 for their TV
were the least likely to bewilling to pay for novel implant 3 (Table 3).
Overall, 45% of the 195 patients were willing to pay for an
implant that had greater longevity than the standard implant
(either novel implant 1 or implant 2). However, only 26% of the 195
patients were willing to pay for an implant that had a decreased
risk of complications without a gain in longevity (novel implant 3).
Discussion
In a previous study using our study population, the overall WTP
for a novel implant over the standard-of-care implant was found to
Table 3
Spending habits and willingness to pay for upgraded implant.
Willingness to pay for:
25 year lifespan with
3% reoperation risk
25 year lifespan
with 5% reoperation risk
15 year lifespan with
1% reoperation risk
How much did you pay
for the car you
typically drive?
Less than $10,000 47.6% 15.0% 10.0%
$10,000 to $25,000 45.9% 28.8% 29.7%
$25,000 to $50,000 48.1% 26.4% 35.2%
More than $50,000 66.7% 40.0% 53.3%
Don't own a car 25.0% 21.4% 18.5%
Chi square (p-value): 7.655 (0.105) 3.328 (0.505) 10.165 (0.038)*
How often do you
typically purchase
or lease a new car?
Every year NA NA NA
Every 1e3 years 50.0% 23.1% 21.4%
Every 4e6 years 51.2% 29.3% 34.1%
Every 6e10 years 51.4% 29.0% 34.3%
Less than every 10 years 38.9% 25.0% 27.8%
Never (Don't own a car) 26.7% 20.0% 17.2%
Chi square (p-value): 6.568 (0.161) 1.152 (0.886) 3.784 (0.436)
How much more are
you willing to pay
over baseline for a
car that comes fully
loaded?
Less than $1,000 39.0% 27.5% 17.5%
$1,000 to $2,500 40.9% 27.7% 25.8%
$2,500 to $5,000 59.0% 28.3% 36.1%
More than $5,000 31.6% 10.5% 42.1%
Chi square (p-value): 7.234 (0.065) 2.671 (0.445) 5.966 (0.113)
How much did you
pay for your TV?
Less than $500 29.0% 16.4% 11.5%
$500 to $1,000 46.8% 27.4% 37.1%
$1,000 to $2,000 55.6% 34.1% 40.0%
More than $2,000 53.3% 33.3% 40.0%
Don't own a TV 87.5% 42.9% 28.6%
Chi square (p-value): 14.725 (0.005)* 5.855 (0.210) 14.440 (0.006)*
How often do you
typically purchase a
new TV?
Every year NA NA NA
Every 1 to 3 years 40.0% 60.0% 40.0%
Every 4 to 6 years 43.9% 25.0% 38.6%
Less than every 6 years 43.4% 24.8% 24.8%
Never (Don't own TV) 87.5% 42.9% 28.6%
Chi square (p-value): 6.023 (0.110)** 4.092 (0.252)** 3.827 (0.281)**
How much more are you
willing to pay for a
more advanced TV over
the base model?
Less than $250 38.5% 22.4% 25.0%
$250 to $750 53.4% 29.3% 37.9%
$750 to $1,500 47.1% 41.2% 23.5%
More than $1,500 60.0% 20.0% 40.0%
Chi square (p-value): 3.984 (0.263)** 3.148 (0.369)** 3.602 (0.308)**
* p < 0.01.
** ¼ More than 20% of cells have expected count of less than 5.
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some of which demonstrated a WTP for an advanced implant in up
to 86% of studied patients [1e5]. While the design of the ques-
tionnaire and description of the implants may play a role in this, it
is important to note the substantial discrepancies between patient
populations at different institutions involved in these studies.
Furthermore, the population of patients in this study were
recruited from a rheumatology specialty clinic and were not
scheduled for or had in the past a joint replacement surgery. Many
previous studies done on WTP data studied only patient who were
either scheduled for or had already had joint replacement surgery.
The concurrent perception of a need for joint replacement in these
previous patient populations would likely increase the WTP over a
population of patients who is, at least, not concurrently considering
joint replacement surgery in the near future.
Both recreational risk taking behavior and health risk taking
behavior were independently associated with a difference in WTP
for a novel implant, though in a different way. Patients who took
many recreational risks were more likely to pay for an implant with
increased longevity (implant 1), while patients who took few, if any,
health risks weremore likely to pay for an implant with a decreased
complication rate (implant 3). One likely reason for this is that
these types of risk-taking behavior are actually not very similar at
all. Many patients who frequently take recreational risks, by doing
extreme sports for instance, may also be patients who take very few
health risks (smoking, unhealthy diet, etc.). Furthermore, patientswho frequently partake in recreational risks may appreciate having
an implant with greater longevity that will allow further use during
recreational activities. Likewise, patients who infrequently take
health risks, by choosing not to smoke for instance, may also place
substantial value on a decreased risk of medical complications, and
are, consequently, more willing to pay for such.
The higher the combined risk score, which combined the full
spectrum of risk-taking behaviors, the more likely the patient was
willing to pay for any of the novel implants. Therefore, in our pa-
tient population, overall risk-taking behavior was associated with a
willingness to pay for both increased longevity of an implant
(implant 1), increased longevity in exchange for a greater risk of
post-operative complications (implant 2), and for decreased post-
operative complications overall (implant 3). Of note, it was
decided that overall risk would best be represented using a com-
bined score that utilized a reversed scale for health risk-taking
behavior. The reason for this decision was that on initial observa-
tion of the data, an opposite trend in WTP was seen in health risk-
taking as opposed to other types of risk-taking (as discussed above).
When considering spending habits of the patients, those who
paid more for their current car were more willing to pay for a novel
implant with a decrease in risk of complications (novel implant 3).
This ﬁnding could be merely due to increased income and wealth
with these patients. As Cross et al. demonstrated in their study,
patients who had higher incomes were more willing to pay
“something” for a total hip replacement [3]. Likewise, Tucker et al.
R. Schwarzkopf, T.L. Kahn / Arthroplasty Today 1 (2015) 14e1818showed that patients who had higher income were more willing to
pay out-of-pocket fees for a joint replacement operation in general
as well as an “advanced technology” joint replacement operation
[5]. Indeed, in a previous study Schwarzkopf et al. demonstrated
that income was signiﬁcantly associated with WTP for all 3 novel
implants [19].
Interestingly, not owning a TV at all was associated with an
increased WTP for novel implant 1 (increased longevity). However,
this “spending habit” can commonly reﬂect a choice to not have a
TV due to cultural and social values rather than reﬂecting actual
ﬁnancial choices or burdens. On the other hand, those patients who
spent the most on their TV (more than $1,000) were more likely to
be willing to pay for a novel implant with a decreased risk of
complications, while those who spent less than $500 on their TV
were the least likely to be willing to pay for a novel implant. Again,
this ﬁnding may be confounded by the income and wealth of the
patients.
There are several limitations to our study. First, when observing
the risk taking behaviors of patients, our study only measured the
patient’s perception of their own risk-taking behavior. A future
study could use a questionnaire to quantify actual risk-taking ac-
tivities rather than simply the patient’s self-reported perception.
Second, the ﬁndings regarding spending behavior are difﬁcult to
interpret given that some behavior inevitably reﬂects personal
wealth, rather than simply spending tendencies. It would be very
difﬁcult to separate these two factors in a study, though one could
better control for income/assets in the study design. Finally, of
clinical relevance, our study population consisted of rheumatology
patients with no current scheduled joint replacement surgery in
their future, while many previous studies on WTP only included
patients who were scheduled for or had already had joint
replacement surgery. We can not exclude the possibility of selec-
tion bias between patients that were willing to participate in the
survey and ones that did not, this limitation is common to all
studies using a survey as part of the methods.Conclusion
While not all types of risk-taking behavior were associated with
differences in WTP for a novel implant, patients with certain risk-
taking behavior, like recreational and health risk-taking (lower),
were signiﬁcantly more likely to be willing to pay for a novel
implant; likewise, patients with higher combined risk scores were
more likely to be willing to pay as well. In regards to spending
habits, patients who spent higher amounts on their current car or
TV were both more likely to be willing to pay for a novel implant.
While further work is needed to fully characterize which patient
groups would be willing to pay for a novel implant in joint
replacement surgery, this study demonstrates that some risk-taking behavior and some spending habits are associated with
patients’ willingness to share the cost for such an implant.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.artd.2014.12.004
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